Pancreas, n (%) 12 (23.1) Major salivary glands, n (%) 11 (21.2) Lacrimal glands, n (%) 9 (17.3) Mediastinal fibrosis, n (%) 6 (11.5) Ear, nose, sinuses, n (%) 5 (9.6) Lung fibrosis, n (%) 5 (9.6) Skin , n (%) 4 (7.7) Pleura, n (%) 4 (7.7) Gall bladder and Biliary ducts, n (%) 4 (7.7) Thyroid, n (%) 3 (5.8) Liver, n (%) 3 (5.8) Kidney (mass) , n (%) 3 (5.8) Pachymeningitis, n (%) 2 (3.8)
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Scientific Abstracts arthritis (n=18, 16%), gynecological diseases (n=11, 10%) kidney stones (n=9, 8%) and others (n=34, 31%). As shown in Table, the frequency of patients with misdiagnosis, was significantly lower in Group 2 (66%) compared to Group 1 (84%). A total of 59 patients (39%) received other long-term treatments, mainly monthly penicillin (n=28), prior to colchicine. There were 41 surgical interventions in 36 patients (24%), before the diagnosis of FMF, the most common being appendectomy in 31, gyneacological operations in 5, cholecystectomy in 3 and others in 2 occasions. It was noted that, the frequency of surgical operations was significantly decreased in Group 2 (12%) compared to Group 1 (27%) (Table) . The presence or absence of MEFV mutations was assessed in 69 patients (46%) before the diagnosis or after to reinforce the diagnosis. As expected, this was significantly more frequent in Group 2 (59%) compared to Group 1 (33%) (Table) . Seventy patients (46%) were diagnosed as FMF only after someone else in the family (n=44) or a friend (n=26) had a similar diagnosis. The frequency of these patients was similar when Group 1 and 2 were compared.
Conclusions:
Although there is considerable decrease in delayed diagnosis of FMF, there is still significant amount of misdiagnoses after the year 2000, even in a geography where FMF is highly prevalent. General clinical examination and lab tests (serum levels of α1-antitrypsin, amylase, lipase, ferritin, creatine phosphokinase (CPK), rheumatoid factor) (RF), ANF, anti-DNA, ANCA), bacteriological and serological tests, radiological examination (chest CT scan), ultrasound examinations of skin and subcutaneous fat (SF) around the nodules, tuberculin skin test and histopathology of nodular skin samples were performed at baseline. Patients were re-tested during the follow up (FUP) when necessary. Results: Female middle-aged patients prevailed in the study group with the disease duration from 1 week to 25 years. Saucer -like depressions as a Pnspecific phenomenon was documented in 28,5% cases. The estimated risk of saucer -like depressions was higher in patients who manifested Pn at the age of >40 years (OR 4,9, 95% CI 2,3-10,4; p<0,0001); this subgroup also showed lesion proneness to confluence and forming of irregular shape conglomerates (OR 2,9, 95% CI 1,45-5,7; p=0,002), tendency to forming large size >3 cm lesions (OR 4,96, 95% CI 2,2-10,97; p<0,0001), and the disease lasting over 3 months (OR 24,9, 95% CI 9,2-67,4; p<0,0001). All pts were re-examined within 1-6 years. Median time to onset of nodules regression was 2 [1;6] months. Recurrences were documented in 66 (35,5%) pts during the follow up. Logistic regression was used for multivariate statistical analysis in order to identify the potential predictors of delayed (>3 months) nodules regression and recurrence risk factors. Used model identified the following predictors of delayed nodules regression (i.e., disease regression): age >40 years (OR 2,58; CI 1,02-6,5; p=0,04), and presence of saucer-like depressions (OR 5,05; CI 1,2-21,7; p=0,03). The sensitivity of used statistical model was 70%, specificity -71%, positive predictive value -74%. Disease duration >3 months (OR 4, 7; CI 2, (0) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) 6; p=0, 0002) was identified by our model as the predictor of recurrences with 60% sensitivity, 78% specificity, and 59% positive predictive value. Conclusions: Pn tends to regress more slowly in pts aged over 40 and in pts having saucer-like depressions. Trend to recurrences is not so evident in Pn, although probability of recurrence increases in pts with longer disease duration at the time of initiation of therapy. 
